Table 1.

Clinical characteristics of participants

Clinical characteristicsNo.
34 
Age, median (range), y 56 (22-73) 
Sex, M/F 21/13 
Diagnosis, no.  
 AML 
 ALL 
 MDS 
 NHL 
 MPN 
 Multiple myeloma 
 Other* 
Donor  
 Matched unrelated 18 
 Matched related 
 Mismatched unrelated 
 Umbilical cord blood 
Stem cell source  
 Peripheral blood stem cells 29 
 Bone marrow 
 Umbilical cord blood 
Conditioning regimen  
 Myeloablative 11 
 Reduced intensity 23 
GVHD prophylaxis  
 Tacrolimus/MTX 17 
 Tacrolimus/sirolimus ± MTX 
 Tacrolimus/MTX/other 
 Tacrolimus or cyclosporine/MMF 
 Ex vivo T-cell depletion 
aGVHD grade at enrollment  
 II 10 
 III 22 
 IV 
Time from aGVHD onset to day 1 of BV, median (range) 31 d (6-185) 
Time from day 0 of HCT (or DLI) to day 1 of BV, median (range) 88 d (28-371) 
Category of SR-aGVHD  
 Progressing or not improving on initial steroids 25 
 Flare upon steroid tapering 
BV dose level  
 0.6 mg/kg IV weekly × 3 
 0.9 mg/kg IV weekly × 3 
 0.6 mg/kg IV every other week × 4 10 
 0.8 mg/kg IV every other week × 4 18 
Clinical characteristicsNo.
34 
Age, median (range), y 56 (22-73) 
Sex, M/F 21/13 
Diagnosis, no.  
 AML 
 ALL 
 MDS 
 NHL 
 MPN 
 Multiple myeloma 
 Other* 
Donor  
 Matched unrelated 18 
 Matched related 
 Mismatched unrelated 
 Umbilical cord blood 
Stem cell source  
 Peripheral blood stem cells 29 
 Bone marrow 
 Umbilical cord blood 
Conditioning regimen  
 Myeloablative 11 
 Reduced intensity 23 
GVHD prophylaxis  
 Tacrolimus/MTX 17 
 Tacrolimus/sirolimus ± MTX 
 Tacrolimus/MTX/other 
 Tacrolimus or cyclosporine/MMF 
 Ex vivo T-cell depletion 
aGVHD grade at enrollment  
 II 10 
 III 22 
 IV 
Time from aGVHD onset to day 1 of BV, median (range) 31 d (6-185) 
Time from day 0 of HCT (or DLI) to day 1 of BV, median (range) 88 d (28-371) 
Category of SR-aGVHD  
 Progressing or not improving on initial steroids 25 
 Flare upon steroid tapering 
BV dose level  
 0.6 mg/kg IV weekly × 3 
 0.9 mg/kg IV weekly × 3 
 0.6 mg/kg IV every other week × 4 10 
 0.8 mg/kg IV every other week × 4 18 

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; DLI, donor leukocyte infusion; F, female; M, male; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; MTX, methotrexate; NHL, non-Hodgkin lymphoma.

*

Other diagnoses: aplastic anemia, blastic plasmacytoid dendritic cell neoplasm, chronic myelomonocytic leukemia.

Other GVHD prophylaxis: 3, ATG; 1, ATG or placebo; 1, bortezomib; 1, Milatuzumab; 1, RGI-2001.